Approaches to the Treatment of NSCLC Harboring KRAS G12C Mutations

home / insights / approaches-to-the-treatment-of-nsclc-harboring-kras-g12c-mutations

Expert perspectives on the advent of KRAS G12C mutations in non–small cell lung cancer, with a focus on the development of targeted therapies in this setting.

EP. 1: Understanding the Nature of a KRAS G12C Mutation in NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

EP. 2: Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 9th 2022

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

EP. 3: Addressing Inadequate Molecular Testing in Patients With NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 16th 2022

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

EP. 4: Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 16th 2022

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

EP. 5: Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 23rd 2022

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

EP. 6: Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

EP. 7: 2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

EP. 8: KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.